AN2 Total Current Assets from 2010 to 2024

ANTX Stock  USD 1.37  0.02  1.44%   
AN2 Therapeutics Total Current Assets yearly trend continues to be fairly stable with very little volatility. Total Current Assets will likely drop to about 61.4 M in 2024. Total Current Assets is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. View All Fundamentals
 
Total Current Assets  
First Reported
2010-12-31
Previous Quarter
110.5 M
Current Value
61.4 M
Quarterly Volatility
37.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AN2 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AN2 Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 73.1 M, Interest Expense of 620.7 K or Selling General Administrative of 7.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.68. AN2 financial statements analysis is a perfect complement when working with AN2 Therapeutics Valuation or Volatility modules.
  
Check out the analysis of AN2 Therapeutics Correlation against competitors.
For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

Latest AN2 Therapeutics' Total Current Assets Growth Pattern

Below is the plot of the Total Current Assets of AN2 Therapeutics over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. AN2 Therapeutics' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AN2 Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Current Assets10 Years Trend
Slightly volatile
   Total Current Assets   
       Timeline  

AN2 Total Current Assets Regression Statistics

Arithmetic Mean26,125,664
Geometric Mean11,289,403
Coefficient Of Variation142.59
Mean Deviation30,153,107
Median5,700,000
Standard Deviation37,251,313
Sample Variance1387.7T
Range106.3M
R-Value0.73
Mean Square Error703.5T
R-Squared0.53
Significance0
Slope6,059,613
Total Sum of Squares19427.2T

AN2 Total Current Assets History

202461.4 M
2023110.5 M
202298.6 M
202160.1 M
20204.2 M

About AN2 Therapeutics Financial Statements

AN2 Therapeutics investors use historical fundamental indicators, such as AN2 Therapeutics' Total Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AN2 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Assets110.5 M61.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.